Wealthy Biotech Trader

ELEVAI Labs Reports Q1 Earnings — Revenue Grows 330%

ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, reported its financial results for the first quarter ended March…

Read More »

Elon Musk Praises Novo Nordisk’s Weight-Loss Drug Ozempic as Solution to Childhood Obesity Epidemic

Tesla (NASDAQ: TSLA) and SpaceX CEO Elon Musk has sparked a conversation about childhood obesity and potential solutions after giving…

Read More »

ELEVAI Labs Announces Launch of ELEVAI Biosciences and ELEVAI Skincare Subsidiaries

ELEVAI Labs established two subsidiaries: ELEVAI Biosciences, Inc., and ELEVAI Skincare, Inc. ELEVAI Biosciences will focus on acquiring and developing…

Read More »

ELEVAI Labs Acquires Exclusive License to Develop and Commercialize Novel Assets to Treat Obesity and Muscle Loss Prevention

The agreement adds two drug candidates to the company’s product pipeline, “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”,…

Read More »

ELEVAI Labs Releases Global Distribution Partnership Overview Featuring $4.9 Million in Potential Top Line Revenue Commitments

The company’s international distribution agreements have a contracted cumulative minimum purchase requirement of up to $4.9 million over the first…

Read More »

ELEVAI Labs Signs International Distribution Agreement to Enter Taiwan Market

The Asia-Pacific market represents a $13 billion prestige skincare and luxury haircare market opportunity, with the Taiwan deal giving the…

Read More »

Global Obesity Drug Market to Grow 16x – Top Weight-Loss Stocks to Watch in 2024

With the weight-loss pharma sector poised for exponential future growth, here’s the skinny on the top obesity drug stocks investors…

Read More »

ELEVAI Labs Posts Record Full Year 2023 and Q4 Earnings

The company also reported record Q4 2023 revenue of $698,591, up 403% over the previous quarter. Elevai Labs Inc. (NASDAQ:…

Read More »

ELEVAI Labs Launches E-Commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in $19.7B Global Physician Dispensed Cosmeceutical Market

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of…

Read More »

ELEVAI Labs Signs Worldwide License Deal for Proprietary Stem Cell Manufacturing Technology

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an…

Read More »
Back to top button